Investor Relations
Mast Out® (an intramammary infusion product containing Nisin) is under development as an alternative to traditional antibiotics for the treatment of mastitis in lactating cows. The safety profile of Nisin may allow for the use of Mast Out® in the U.S. without milk discard or meat withhold requirements.
- 8-K
- White Paper: Treating Mastitis Without a Loss of Milk Revenue
- Case Study: Optimization of Milk Revenues Through the Improved Management of Subclinical Mastitis
In addition, we are exploring product line enhancements to First Defense®, such as claims to prevent scours caused by additional enteric pathogens. In the second quarter of 2009, we entered into an exclusive technology license after achieving proof of concept in studies using this enabling technology against scours covered by rotavirus.
While we continue to pursue internally funded product development programs, we remain interested in acquiring new products and technologies that fit within our sales focus on the dairy and beef industries.
ImmuCell
is a public biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Our product focus encompasses prevention, diagnosis and treatment of economically important bovine diseases.
Investor Relations:
Michael F. Brigham
President & CEO
ImmuCell Corporation
56 Evergreen Drive
Portland, Maine 04103
207-878-2770
mbrigham@immucell.com
For up-to-date quotes:
• FlashQuote
• Yahoo Finance
• InfoQuote